TY - JOUR
T1 - Factors associated with asthma attack recurrence in Ecuadorian children
T2 - longitudinal study of potential impact of the COVID-19 pandemic lockdown
AU - Mena-Bucheli, Santiago
AU - Morillo, Diana
AU - Chico, Martha
AU - Ochoa-Aviles, Angelica
AU - Rodas-Espinoza, Claudia
AU - Arteaga, Karen
AU - Maldonado, Augusto
AU - Rodriguez, Alejandro
AU - Figueiredo, Camila A.
AU - Cruz, Alvaro A.
AU - Romero-Sandoval, Natalia
AU - Chis Ster, Irina
AU - Cooper, Philip J.
N1 - Publisher Copyright:
© Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY. Published by BMJ Group.
PY - 2025/11/27
Y1 - 2025/11/27
N2 - Background The COVID-19 pandemic caused a major disruption in access to and use of health resources and facilities. There are limited longitudinal data from low-resource settings on the impact of pandemic mitigation strategies and medication use on asthma attacks in children. Methods We did a longitudinal study of risk factors for asthma attack recurrence among children aged 5–17 years presenting with an attack to emergency rooms in public hospitals in Ecuador. Children were followed for at least 12 months by monthly telemonitoring. Cox regression models for multiple recurrences were used to identify potential risk factors. Results 213 asthmatic children were recruited from May 2019 to March 2020 when recruitment was interrupted by a COVID-19 lockdown: 97% were followed for at least 12 months (median 419 days, IQRs 393–421days). In multivariable analysis, the lockdown effect (adjusted HR 0.35, 95%CI 0.22 to 0.56, p<0.001) and use of inhaled corticosteroids (adjusted HR 0.64, 95%CI 0.43 to 0.93, p=0.020) were strongly protective against recurrence while short-acting β2 agonist use was associated with increased recurrence, particularly among children with a previous asthma diagnosis (interaction p=0.033). Other risk factors were household mould (adjusted HR 1.42, 95%CI 1.03 to 1.95, p=0.031) and number of prerecruitment emergency room visits (adjusted HR 1.05, 95%CI 1.00 to 1.11, p=0.040). Conclusion Our data show in a population of asthmatic children from marginalised urban neighbourhoods in Ecuador, that use of inhaled corticosteroids was protective against asthma attack recurrence as were mitigation strategies implemented during the COVID-19 pandemic to reduce transmission of respiratory viruses.
AB - Background The COVID-19 pandemic caused a major disruption in access to and use of health resources and facilities. There are limited longitudinal data from low-resource settings on the impact of pandemic mitigation strategies and medication use on asthma attacks in children. Methods We did a longitudinal study of risk factors for asthma attack recurrence among children aged 5–17 years presenting with an attack to emergency rooms in public hospitals in Ecuador. Children were followed for at least 12 months by monthly telemonitoring. Cox regression models for multiple recurrences were used to identify potential risk factors. Results 213 asthmatic children were recruited from May 2019 to March 2020 when recruitment was interrupted by a COVID-19 lockdown: 97% were followed for at least 12 months (median 419 days, IQRs 393–421days). In multivariable analysis, the lockdown effect (adjusted HR 0.35, 95%CI 0.22 to 0.56, p<0.001) and use of inhaled corticosteroids (adjusted HR 0.64, 95%CI 0.43 to 0.93, p=0.020) were strongly protective against recurrence while short-acting β2 agonist use was associated with increased recurrence, particularly among children with a previous asthma diagnosis (interaction p=0.033). Other risk factors were household mould (adjusted HR 1.42, 95%CI 1.03 to 1.95, p=0.031) and number of prerecruitment emergency room visits (adjusted HR 1.05, 95%CI 1.00 to 1.11, p=0.040). Conclusion Our data show in a population of asthmatic children from marginalised urban neighbourhoods in Ecuador, that use of inhaled corticosteroids was protective against asthma attack recurrence as were mitigation strategies implemented during the COVID-19 pandemic to reduce transmission of respiratory viruses.
KW - Asthma Epidemiology
KW - Paediatric asthma
UR - https://www.scopus.com/pages/publications/105023093913
U2 - 10.1136/bmjresp-2024-002509
DO - 10.1136/bmjresp-2024-002509
M3 - Artículo
C2 - 41314662
AN - SCOPUS:105023093913
SN - 2052-4439
VL - 12
JO - BMJ Open Respiratory Research
JF - BMJ Open Respiratory Research
IS - 1
M1 - e002509
ER -